美国 · 平台与数据 · Morningstar

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

来源：Morningstar · 美国 1 天前

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company…

在 Morningstar 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.morningstar.com)

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

推荐阅读

Westinghouse Air Brake Technologies: 3 Key Takeaways for Long-Term Investors

Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances

Kazia gains as Guggenheim is latest to initiate at Buy on lead asset

Medicare is a bargain. What America can’t afford is private health insurance.

Initial jobless claims highlight Thursday’s economic calendar

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

分享

推荐阅读

Westinghouse Air Brake Technologies: 3 Key Takeaways for Long-Term Investors

Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances

Kazia gains as Guggenheim is latest to initiate at Buy on lead asset

Medicare is a bargain. What America can’t afford is private health insurance.

Initial jobless claims highlight Thursday’s economic calendar

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge